Montvida O, et al. – Using U.S. Centricity Electronic Medical Records, researchers assessed the persistent glycemic and cardiovascular (CV) risk factor burden over 2 years after treatment intensification (TI) in people with incident type 2 diabetes receiving antidiabetic and cardioprotective therapies. Study participants included 276,884 patients with incident type 2 diabetes who intensified metformin. Investigators found that the proportion of patients with consistently uncontrolled HbA_1c increased from 31% in 2005 to 41% in 2014. Of those on lipid-modifying drugs, 41% and 37% had consistently high low-density lipoprotein and triglycerides levels over 2 years. They observed that 29% had consistently uncontrolled systolic blood pressure (SBP) despite being on antihypertensive therapies. Overall, more than one-third of participants had uncontrolled HbA_1c, lipid, and SBP levels, and more than one-half had two CV risk factors that were simultaneously uncontrolled after TI among patients on multiple therapies for risk factor control.